NCT06548152Recruiting
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
AQUALIS: Quality of Life of Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib in France: a Retrospective Observational Study Based on Data Extracted From the PLATON Database
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting. The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and twelve months after, in a real-life setting.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 17 Jul 2024
- Start date
- 28 Apr 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- AstraZeneca
- NCT number
- NCT06548152
What you commit to
- Study type: Observational
- Planned participants: 120
- From 28 Apr 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- The following patients will be eligible for inclusion in the AQUALIS study :
- -Patient enrolled in the PLATON database
- -Patient ≥18 years old
- -Treatment naïve CLL patient treated with acalabrutinib in a real life setting. Treatment pattern is Acala mono or Acala + Obinutuzumab
- -Patient who do not object to his health data collected in PLATON study being re-use for analysis/research purpose
- -Patients who started Acala but discontinued before 12 months are also included.
- Exclusion criteria:
- -Pregnant women
- -Patients under protection of justice
- -Patients over the age of 18 and unable to express their non-opposition
- -Patients with prior CLL treatments
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Saint-Affrique | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.